Kodiak Sciences (NASDAQ:KOD) Price Target Raised to $120.00

Kodiak Sciences (NASDAQ:KOD) had its price objective raised by UBS Group from $80.00 to $120.00 in a research note issued to investors on Monday, MarketBeat reports. They currently have a buy rating on the stock.

Other equities research analysts also recently issued reports about the stock. JPMorgan Chase & Co. raised their target price on shares of Kodiak Sciences from $56.00 to $66.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. The Goldman Sachs Group initiated coverage on Kodiak Sciences in a research report on Thursday, September 24th. They set a “neutral” rating and a $36.00 price target on the stock. Wall Street Zen lowered Kodiak Sciences from a “sell” rating to a “strong sell” rating in a report on Saturday, September 26th. HC Wainwright raised their price objective on Kodiak Sciences from $58.00 to $96.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Kodiak Sciences in a research note on Friday, July 10th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $100.43.

Kodiak Sciences Stock Performance

NASDAQ:KOD opened at $94.80 on Monday. Kodiak Sciences has a fifty-two week low of $10.94 and a fifty-two week high of $98.80. The stock has a market capitalization of $5.96 billion, a P/E ratio of -22.63 and a beta of 2.18. The company’s 50-day simple moving average is $41.32 and its 200-day simple moving average is $38.77.

Kodiak Sciences (NASDAQ:KOD) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.09). On average, research analysts forecast that Kodiak Sciences will post -3.89 EPS for the current year.

Insider Buying and Selling

In related news, Director Bros. Advisors Lp Baker bought 33,726 shares of the company’s stock in a transaction on Tuesday, September 29th. The shares were bought at an average price of $85.05 per share, with a total value of $2,868,396.30. Following the transaction, the director owned 20,191,214 shares in the company, valued at approximately $1,717,262,750.70. This trade represents a 0.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have purchased 1,941,755 shares of company stock valued at $156,986,026. 44.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. V Square Quantitative Management LLC purchased a new position in shares of Kodiak Sciences in the first quarter worth $26,000. Westfuller Advisors LLC purchased a new stake in shares of Kodiak Sciences during the first quarter valued at $26,000. EverSource Wealth Advisors LLC increased its position in shares of Kodiak Sciences by 1,221.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock valued at $28,000 after acquiring an additional 916 shares during the period. KBC Group NV acquired a new position in shares of Kodiak Sciences in the 1st quarter valued at $39,000. Finally, E Fund Management Co. Ltd. purchased a new position in Kodiak Sciences in the 2nd quarter worth $228,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Kodiak Sciences News Summary

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Strong Phase 3 results drive investor enthusiasm. Zenkuda and KSI-501 reportedly achieved their primary goals in the DAYBREAK study for wet age-related macular degeneration, meeting key endpoints against Eylea. Kodiak is advancing Zenkuda toward a biologics license application (BLA), creating a potential path toward regulatory review in a large retinal-drug market. Zenkuda positive wet AMD data article
• Positive Sentiment: HC Wainwright raised its long-term earnings outlook. The firm lifted its FY2029 EPS forecast to $1.76 from $0.18 and its FY2030 forecast to $5.81 from $3.04. It maintained a Buy rating and a $96 price target, while projecting a transition from losses in FY2027 and FY2028 to profitability in FY2029. Kodiak Sciences analyst estimates
• Positive Sentiment: Insider purchases provide a confidence signal. Director Bros. Advisors LP Baker reported multiple purchases totaling roughly 1.94 million shares for approximately $157 million across September 28–29. The buying materially increased the director’s already substantial ownership stake. SEC insider ownership filing
• Neutral Sentiment: Near-term analyst revisions were mixed. HC Wainwright slightly reduced its FY2027 loss estimate to $3.36 per share from $3.27, but improved forecasts for later years as it incorporated the potential impact of Zenkuda.
• Negative Sentiment: Investors face substantial execution and financing risks. Kodiak has no current revenue and continues to burn cash, making a future share offering possible. Unusually high put-option buying also suggests some traders are positioning for volatility or a pullback after the dramatic rally. Kodiak valuation and financing risks article

Kodiak Sciences Company Profile

Kodiak Sciences Inc (NASDAQ: KOD) is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company’s research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration.

Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.